F 901318

Drug Profile

F 901318

Alternative Names: F901318

Latest Information Update: 03 Jul 2017

Price : $50

At a glance

  • Originator F2G
  • Class Antifungals; Small molecules
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Aspergillosis

Most Recent Events

  • 24 May 2017 Chemical structure information added
  • 22 May 2017 F2G completes the phase I ORALMAD trial in Healthy volunteers in United Kingdom (NCT02737371)
  • 22 Apr 2017 Adverse events and pharmacokinetics data from a phase I trial in Aspergillosis (PO; Immediate-release tablet) presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top